

Lactobacillus reuteri in the Management of Infantile Colic Helena Gaitan, PA-S and Katherine Evans, PA-S James Madison University, Harrisonburg, VA

INTRODUCTION

- Infantile colic (IC) is more than 3 hours of crying per per week, for over 3 weeks, in an otherwise healthy,
- Affects as many as 1 in 4 newborns²
- Begins in the first 2 weeks of life and usually goes av intervention by 3 or 4 months of age
- Has significant impacts on the infant, the parents, ar
- Studies have found colic to be associated with mater shaken baby syndrome, and early cessation of breas
- Gut microbiota of infants with colic have less bacteri lower concentrations of protective, anti-inflammatory as lactobacilli⁶
- Studies have revealed correlation of intestinal dysbid
- Evidence suggests that Lactobacillus reuteri may lea resolution of IC

CLINICAL QUESTION

Is Lactobacillus reuteri more effective than placebo in time in breastfed infants with colic?

METHODS

Figure 1: PRISMA Flow Diagram

0	
Identification	Records identified through PubMed with search terms " <i>Lactobacillus</i> <i>reuteri</i> " AND "colic" and limited to "Clinical Trials" and "Human Species" (n = 17)
screening	Records after duplicates removed (n = 17) Records exclude (n = 9) - 1 due to comparison with simethico - 3 because <i>L. reuteri</i> combined with
	Records screened (n = 17) - 1 because study was focused on gu - 2 because it was a different strain o - 1 because feces sample was their o 1 because it was focused on safety
Eligibility	Full-text articles assessed for eligibility (n = 8) Full-text articles excluded, v (n = 5) - 1 only single blinded and didn't spec - 1 did not specifically look at decreas
cluded	Studies included in qualitative synthesis (n = 3) - See below
Inc	 Studies included in quantitative synthesis (meta-analysis) (n = 3) Lactobacillus reuteri DSM 17938 in Infantile Colic: A Randomized, Double-Blin Controlled Trial by Savino, F., Cordisco, L., Tarasco, V, et al. Probiotics for Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled Lactobacillus reuteri DSM 17938 by Chau, K., Lau, E., Greenberg, S., et al. Lactobacillus reuteri DSM 17938 for the Management of Infantile Colic in Brea Randomized, Double-Blind, Placebo-Controlled Trial by Szajewska, H., Gyrcz

D Γ ΩΤΗ ΤΩ

day, over 3 days well-fed infant ¹		<u>Study 1</u> Chau et al. ⁸	<u>Study 2</u> Savino et al. ⁹	<u>Study 3</u> Szajewska et al. ¹⁰
way without nd clinicians ^{3,4} ernal depression, stfeeding ⁵	Objective	Investigated Lactobacillus reuteri DSM 17938 for treating infant colic vs. placebo in Canadian infants	To test the efficacy of Lactobacillus reuteri in treating infantile colic and to evaluate its relationship to gut microbiota	To determine if the administration of Lactobacillus reuteri is beneficial in the treatment of breastfed infants with infantile colic
ial diversity and y bacteria, such	Study Design	Double-blind, Placebo controlled RCT	Double-blind, Placebo controlled RCT	Double-blind, Placebo controlled RCT
osis with IC ^{2,7} ad to the	Test Number	24	25	40
	Control Number	28	21	40
reducing crying	Probiotic Treatment	Suspension of freeze-dried <i>L. reuteri</i> DSM 17938 1x10 ⁸ per 5 drops in a mixture of sunflower oil, medium-chain triglyceride oil, & silicon dioxide	Suspension of freeze-dried <i>L. reuteri</i> DSM 17938 1x10 ⁸ per 5 drops in a mixture of sunflower oil & medium-chain triglyceride oil	Suspension of freeze-dried <i>L.</i> <i>reuteri</i> DSM 17938 1x10 ⁸ per 5 drops in a mixture of sunflower oil & medium-chain triglyceride oil with added vitamin D3
	Placebo Treatment	Combination of sunflower oil, medium-chain triglyceride oil, & silicon dioxide	Combination of sunflower oil & medium-chain triglyceride oil	Combination of sunflower oil & medium-chain triglyceride oil, with vitamin D3 added
d ne	Age	< 5 months	2 – 16 weeks	3 weeks to 6 months
It microbiota f <i>Lactobacillus</i> observed outcome of <i>L. reuteri</i> vs. efficacy	Gestational Age at Delivery	≥ 37 weeks	Term	Full-term
vith reasons	Feeding Type	Exclusively breastfed	Exclusively breastfed	Predominantly breastfed
cify oil ingredients se in crying time ad of preventative	Follow-up Period	Day 7, 14, 21	Day 7, 14, 21	Day 7, 14, 21, 28
nd, Placebo-	Conclusion	Infants in L. reuteri group experienced more reduction in crying time compared to placebo	L. reuteri improves symptoms of infantile colic in breastfed infants with colic	L. reuteri reduces crying time in predominantly breast-fed infants with colic
d Trial Investigating astfed Infants: A uk, E, & Horvath, A.	NNT – Day 7, 14, 21, 28	8, 3, 2, N/A	2, 3, 4, N/A	7, 2, 2, 3

Set 350 Minu 300 . 250 **.** 200 ing 150 E 100 50 0 21 0 21 Placebo

- L. reuteri is significantly more effective than placebo in reducing crying-time in infants with colic
- No adverse effects were seen in those receiving *L. reuteri*
- The findings can only truly be applied to breastfed infants
- Future studies need to address formula-fed infants
- Future studies should improve sample size, and find ways to verify daily diary tracking and product administration
- There is some suggestion *L. reuteri* given prophylactically could prevent the development of colic,^{11,12} but more studies are needed in this area in order to draw any conclusions
- Based on the findings of this analysis, breastfed infants with established colic should be treated with L. reuteri supplementation

ACKNOWLEDGEMENTS

- Donna M, Roberts MD, Ostapchuk M, M.D., et al. Infantile colic. Am Fam Physician. 2004;70(4):735-40. Dubois N, Gregory K. Characterizing the intestinal microbiome in infantile colic: Findings based on an integrative review of the literature. Biological Research For Nursing. 2016;18(3), 307-15. Turner T, MD, MPH, Palamountain M, MD. Infantile colic: Clinical features and diagnosis. In: UpToDate Feldman M, Grover S (Ed). Up To Date. Waltham, MA: 2019. https://www.uptodate.com/contents/infantile-colic-clinical-features-and-diagnosis. Accessed on October 1, 2019. Camilleri M, Park SY, Scarpato E, Staiano A. Exploring hypotheses and rationale for causes of infantile colic. *Neurogastroenterol Motil.* 2017;29(2):10.1111/nmo.12943. doi:10.1111/nmo.12943 5. Sung V, D'Amico F, Cabana MD, et al. Lactobacillus reuteri to treat infant colic: A meta-analysis. Pediatrics. 2018;141(1):e20171811 Weerth C, PhD, Fuentes S, PhD, Puylaert P, MSc, et al. Intestinal microbiota of infants with colic: Development and specific signatures. *Pediatrics.* 2012;131(2): 550-58. Tintore M, Colome G, Santas J, et al. Gut microbiota dysbiosis and role of probiotics in infant colic. Arch Clin Microbiol. 2017; 8(4):56. doi:10.4172/1989-8436.100056 Chau K, Lau E, Greenberg S, et al. Probiotics for infantile colic: A randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. Journal of Pediatrics. 2015; 166(1): 74-78. Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: A randomized, double-blind, placebo-controlled trial. *Pediatrics*. 2010; 126(3):e526-33.
- 10. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: A randomized, double-blind, placebo-controlled trial. *The Journal of Pediatrics*. 2013; 162(2):257-62. 11. Indrino F, Di Mauro A, Riezzo G, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: A randomized clinical trial. JAMA Pediatr. 2014; 168(3):228-33.
- 12. Savino F, Ceratto S, Poggi E, et al. Preventive effects of oral probiotic on infantile colic: A prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938. Bene Microbes. 2015; 6(3):245-51.





CONCLUSIONS

We would like to thank Dr. Massey and Carolyn Schubert for their guidance throughout this research project.

REFERENCES